Dabrafenib Completed Phase 2 Trials for Melanoma Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT01153763A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
NCT01619774An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
NCT01682213Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation